Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders
- ANAVEX® Life Sciences Corp.
- May 11, 2011
- 1 min read
Expert Opin Ther Targets. 2011 May ; 15(5): 557–577. doi:10.1517/14728222.2011.560837.
Hayashi Teruo*, Tsai Shang-Yi, Mori Tomohisa, Fujimoto Michiko, and Su Tsung-Ping
